To evaluate the efficacy of immunotherapy for venous tumour thrombus (VTT) in patients with metastatic renal cell carcinoma (RCC), particularly given the poor prognosis associated with VTT.
Key Findings:
The median VTT diameter was 22 mm, with varying classifications of thrombus extension, indicating the complexity of treatment.
The majority of patients were treated first-line with ICI-based therapy, suggesting its role as a standard approach.
Six patients underwent delayed nephrectomy and thrombectomy after treatment, highlighting potential surgical options post-therapy.
Interpretation:
The study suggests that ICI-based therapies may be effective in managing VTT in metastatic RCC, although detailed efficacy data remains limited, underscoring the need for further research.
Limitations:
The study is retrospective and may be subject to selection bias, which could affect the reliability of the findings.
Limited sample size of 44 patients may affect the generalizability of the findings, necessitating larger studies.
Data on the efficacy of immunotherapy agents in RCC patients with VTT is scarce, indicating a gap in current research.
Conclusion:
ICIs show promise in treating metastatic RCC with VTT, warranting further investigation in larger, prospective studies to validate these findings.
by Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, Nieves Martinez-Chanza, Victor Gaillard, Roberto Luigi Cazzato, Romain Boissier, Gaëlle Margue, Philippe Boudier, Denis Maillet, Marine Gross-Goupil, Jean-Christophe Bernhard, Philippe Barthélémy
